Prime medicine receives up to $15 million from cystic fibrosis foundation to advance hotspot and passige™ prime editors for cystic fibrosis

Cambridge, mass., jan. 25, 2024 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the cystic fibrosis foundation (cf foundation) has agreed to provide the company with up to $15 million to support the development of prime editors for the treatment of cystic fibrosis (cf).
PRME Ratings Summary
Quant
PRME Quant Ranking
Sector
Industry
Quant Rating
Quant Score